Anthropic was expected to price its initial public offering on November 18, with Nasdaq trading under the symbol ANT expected to begin November 19. The proposed deal comprises 825 million Class A shares priced between $70 and $78 each. At the top of that range, the full offering would represent $64.35 billion in gross value before fees and other expenses. Those dates and figures describe an expected transaction, not a completed listing. Until pricing is announced and trading begins, the range remains indicative, and the first public market price may differ from the offering price. Investors assessing the deal should keep the timetable, proposed terms and eventual trading outcome separate.

The offering has two components. Anthropic would sell 801,351,354 shares, while existing holders would sell 23,648,646. At $78 per share, the company’s portion would generate about $62.5 billion before fees. The remaining shares would provide proceeds to the selling holders rather than to Anthropic. That distinction matters when considering what the transaction could fund: the gross value of all shares is not the same as the amount received by the company. The final allocation, price and costs would affect proceeds. The proposed share count also does not, by itself, show how much of the company would remain available to trade after the offering or how ownership may change over time.

The indicative range implies a valuation of approximately $1.02 trillion on a non-diluted basis and up to about $1.4 trillion on a fully diluted basis at $78. These figures use different share-count assumptions, so they should not be treated as competing estimates of the same measure. The fully diluted framing includes additional potential shares, while the non-diluted calculation uses a narrower base. The gap is therefore a reminder to check the denominator behind any valuation comparison. A larger fully diluted figure does not mean that every potential share has already been issued, and the proposed range is not a guarantee of the market value after trading starts.

Reported market estimates put demand at roughly six times the offering. That figure suggests interest ahead of pricing, but it is not a final, exchange-verified subscription count. It should not be read as proof that every indication will become a funded order, nor as a measure of how shares will trade once public buying and selling begin. Demand estimates can change as the deal progresses and may reflect different categories of interest. The final price, allocation and aftermarket liquidity will provide separate information. Investors should preserve the distinction between reported demand and confirmed transaction data, especially when interpreting a multiple that may sound precise but remains an estimate.

Anthropic also planned a separate $26 billion placement involving Google, Nvidia, AMD, Broadcom, Micron, Microsoft and TSMC. This placement is distinct from the 825 million shares in the proposed public offering. It should not be added to the IPO’s share count or treated as public-market demand for ANT. The participants span cloud, semiconductor and technology businesses, but the stated plan alone does not establish what each participant will receive, the placement terms, or the future commercial effects. The two transactions may matter to the company’s financing picture in different ways. Investors should track their terms separately as more information becomes available.

The company reported third-quarter revenue of $16.96 billion, up 47% quarter over quarter. That is a substantial sequential increase, but one quarter does not establish a durable growth rate. The reported figure should be considered alongside the period covered, revenue recognition and any additional operating information released with the offering. The 47% comparison is quarter over quarter, not year over year, and should not be described as an annual growth rate. No unsupported October annualized revenue figure is needed to interpret this result. Keeping the comparison period clear helps prevent a short-term change from being mistaken for a longer-term trend.

A large proposed valuation puts attention on what investors are paying for future business performance as well as reported revenue. Yet the figures available here do not establish a complete valuation case: they do not by themselves show margins, cash generation, capital requirements, customer concentration, or the durability of demand. Investors can compare the proposed valuation measures with the company’s reported operating figures, while recognizing that a simple ratio cannot resolve those unanswered questions. The offering range also places a value on shares before public trading establishes a market price. Once trading begins, prices can move as participants reassess information, liquidity and expectations.

The IPO timetable creates several distinct information points. Pricing expected November 18 would set the offer price within, or potentially outside, the stated indicative terms if those terms change. Expected Nasdaq trading on November 19 would then expose ANT shares to public-market order flow. Neither date guarantees that every detail will remain unchanged. Investors following the event can distinguish the announced final offer price, the number of shares allocated, the split between company and existing-holder sales, and the opening and subsequent market prices. Each answers a different question. The offer price records transaction terms; later prices show where trades occur under prevailing market conditions.

For broader markets, the proposed listing may attract attention to technology valuations and appetite for large offerings. That is a possible area of interest, not evidence that the IPO will move the Nasdaq in a particular direction. The NAS100 is a broad index instrument, not direct Anthropic exposure, and it is not a hedge for ANT or the offering. Its price reflects a basket of large non-financial Nasdaq-listed companies and broader market forces. A trader using NAS100 to follow general Nasdaq conditions should keep the distinction between index exposure and company-specific exposure clear. The instrument cannot reproduce the return of Anthropic shares.

The key figures describe a proposed deal rather than a completed market outcome: 825 million shares, a $70 to $78 indicative range, $64.35 billion in maximum gross offering value at the top, and a separate planned $26 billion placement. The company’s proposed 801,351,354-share sale and existing holders’ 23,648,646 shares have different recipients of proceeds. Revenue was $16.96 billion in the third quarter, up 47% quarter over quarter. Reported demand near six times the offering remains an estimate. Keeping those facts in their proper categories supports a more careful reading of the transaction as pricing approaches.

As pricing and the expected first trading session draw near, useful questions are concrete: What final price is announced? How many shares are allocated to each group? What company proceeds remain after fees? Does the listing begin on the expected date? How does ANT trade after opening, and how much volume accompanies any move? Answers can refine the picture, but they do not eliminate uncertainty around valuation or future performance. A proposed IPO is one event in a company’s financing and ownership history. Its eventual public-market performance will depend on information and trading conditions beyond the indicative range and pre-pricing demand estimate.

Follow broader Nasdaq markets
Key Levels

Trading Insight

Anthropic’s proposed IPO combines a $70 to $78 indicative range, 825 million shares and reported demand of roughly six times the offering. Treat that demand figure as a market estimate, not a final subscription count. Separate the company’s proposed share sale from existing-holder sales, and compare the approximately $1.02 trillion non-diluted valuation with the up to $1.4 trillion fully diluted framing using their different share-count assumptions. NAS100 offers broad Nasdaq index exposure only; it is not direct Anthropic exposure and is not a hedge for ANT.